Emergent BioSolutions to Release First Quarter 2022 Financial Results and Conduct Conference Call on April 28, 2022
08 avr. 2022 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., April 08, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, April 28, 2022, at 5:00 pm eastern time to discuss the financial...
Emergent BioSolutions Provides Corporate Governance Update
23 mars 2022 16h05 HE
|
Emergent BioSolutions
Zsolt Harsanyi, Ph.D. Appointed Chairman of the BoardKeith Katkin Appointed to the BoardEliminates Role of Executive ChairmanAppoints New Chairs of Audit, Strategic Operations, and Scientific Review...
Emergent BioSolutions to Participate in Investor Conferences
14 mars 2022 16h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., March 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
Emergent BioSolutions Initiates Phase 1 Study Evaluating Potential Intranasal Treatment for Cyanide Poisoning
11 mars 2022 06h34 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., March 11, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety,...
Emergent BioSolutions Reports Financial Results for Fourth Quarter 2021
24 févr. 2022 16h05 HE
|
Emergent BioSolutions
Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and Adjusted EBITDA of $518M, in line with prior guidanceUpdates full year 2022...
Emergent BioSolutions to Release Fourth Quarter 2021 Financial Results and Conduct Conference Call on February 24, 2022
07 févr. 2022 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, February 24, 2022 at 5:00 pm eastern time to discuss the...
Founder and Executive Chairman of Emergent BioSolutions Announces Retirement
14 janv. 2022 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Jan. 14, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that Fuad El-Hibri, founder and executive chairman, has decided to retire effective April...
Emergent BioSolutions Announces 2022 Financial Guidance, Provides Preliminary 2021 Results
09 janv. 2022 14h00 HE
|
Emergent BioSolutions
Expects a re-baseline of operations with stable revenue contributions from core products and services business in 2022, guiding to total revenues of $1.45 billion at the midpoint and Adjusted EBITDA...
Emergent BioSolutions to Participate in Investor Conferences
03 janv. 2022 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive management team will participate in the following...
Emergent BioSolutions Announces Initiation of Phase 1 Study Evaluating Its Universal Influenza Vaccine Candidate
16 déc. 2021 07h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the first participant dosed in its phase 1 study, EBS-UFV-001, evaluating the safety,...